Prostate specific antigen: The past, present and future

Current Urology

Volumn 6, Issue 4, 2012, Pages 175-178

  Gill, Harcharan ^a   Wu, Jonathan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; CANCER SCREENING; CONTRAST ENHANCEMENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 84874075914     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000343535     Document Type: Review

References (27)

1. U.S. Preventive Services Task Force: Screening for prostate cancer: draft recommendation statement. http://www.uspreventiveservicestaskforce. org/uspstf12/prostate/draftrec3.htm
2. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA: American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
3. Carroll P, Albertsen PC, Greene K, Babaian RJ, Carter HB, Gann PH, Han M,Kuban DA, Sartor AD, Stanford JL, Zietman A: Prostatespecific antigen best practice statement: 2009 update. American Urological Association, 2009. www.auanet.org/content/media/psa09.
4. pdf Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
5. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
6. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, Catalona WJ: What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 2011;29:464-467.
7. Cooperberg MR, Carroll PR, Klotz L: Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011;29:3669-3676.
8. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, Fagerstrom R, Riley TL, Clapp JD, Berg CD, Gohagan JK, Andriole GL, Chia D, Church TR, Crawford ED, Fouad MN, Gelmann EP, Lamerato L, Reding DJ, Schoen RE: Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 2009;7:212-222.
9. Esserman L, Shieh Y, Thompson I: Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302;1685-1692.
10. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-771.
11. Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Blazina I, Gleitsmann K, Rugge JB: Treatments for localized prostate cancer: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No 91. http://www.ncbi. nlm.nih.gov/books/NBK82315/pdf/TOC.pdf
12. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F, de la Taille A: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59:422-429.
13. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011;59:96-105.
14. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, Forgues A, Robert G, Vacherot F, Loric S, Allory Y, Ruffion A, de la Taille A: The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43-49.
15. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180:1975-1978.
16. Rosenkrantz AB, Scionti SM, Mendrinos S, Taneja SS: Role of MRI in minimally invasive focal ablative therapy for prostate cancer. AJR Am J Roentgenol 2011;197:W90-96.
17. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H: MRI of the prostate: clinical relevance and emerging applications. J Magn Reson Imaging 2011;33:258-274.
18. Kirkham AP, Emberton M, Allen C: How good is MRI at detecting and characterizing cancer within the prostate? Eur Urol 2006;50: 1163-1174.
19. Kurhanewicz J, Vigneron D, Carroll P, Coakley F: Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008;18:71-77.
20. Yaligar J, Thakur SB, Bokacheva L, Carlin S, Thaler HT, Rizwan A, Lupu ME, Wang Y, Matei CC, Zakian KL, Koutcher JA: Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness. NMR Biomed 2012;25:113-122.
21. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB: Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002;16:451-463.
22. Rosenkrantz AB, Mannelli L, Kong X, Niver BE, Berkman DS, Babb JS, Melamed J, Taneja SS: Prostate cancer: utility of fusion of T2-weighted and high b-value diffusionweighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging 2011;34:95-100.
23. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S: Prostate cancer screening: the clinical value of diffusionweighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-152.
24. Halpern EJ: Contrast-enahnced ultrasound imaging of prostate cancer. Rev Urol 2006;8(suppl 1):29-37.
25. Frauscher F, Klauser A, Halpern EJ, Horninger W, Bartsch G: Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 2001;357:1849-1850.
26. Frauscher F, Klauser A, Volgger H, Halpern EJ, Pallwein L, Steiner H, Schuster A, Horninger W, Rogatsch H, Bartsch G: Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on prostate cancer detection. J Urol 2002;167:1648-1652.
27. Sanna V, Pintus G, Bandiera P, Anedda R, Punzoni S, Sanna B, Migaleddu V, Uzzau S, Sechi M: Development of polymeric microbubbles targeted to prostate-specific membrane antigen as prototype of novel ultrasound contrast agents. Mol Pharm 2011;8:748-757.